Fuda Cancer Hospital
Rhabdomyosarcoma treatment cost in China typically runs from $85,000 to $142,000 for comprehensive care. Essential procedures like the removal of rhabdomyosarcoma range from $24,500 to $49,500. Total expenses depend on the tumor stage, required therapy cycles, and clinic tier. Patients often find 40% to 60% savings compared to the US. Top cities for this treatment include Guangzhou, Shanghai, and Beijing.
Typical Rhabdomyosarcoma Treatment Costs in China
Bookimed Expert Insight: Advanced stage patients should prioritize clinics specializing in late-stage oncology. Fuda Cancer Hospital offers specialized cryosurgery and NanoKnife technologies for complex cases. For pediatric or adult radiation needs, Dr. Liu Shi Xin at Xiamen Humanity Hospital provides internationally recognized expertise in IMRT. These JCI-accredited facilities offer a high-value alternative for patients needing multidisciplinary care beyond standard chemotherapy protocols.
| China | Turkey | Austria | |
| Removal of rhabdomyosarcoma | from $24,500 | from $15,000 | from $30,000 |
| Radiation therapy for colorectal cancer | from $11,500 | from $7,000 | from $12,000 |
| Radiation Therapy for Sarcomas | from $10,500 | from $3,250 | from $18,000 |
| Chemotherapy for breast cancer | from $14,800 | from $1,200 | from $15,000 |
| Complex treatment of rhabdomyosarcoma | from $85,000 | from $45,000 | - |
No hidden fees – just official clinic prices. Pay at the clinic for Rhabdomyosarcoma treatment and use a flexible installment plan if needed.
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in Rhabdomyosarcoma treatment and have the necessary licenses to serve international patients worldwide.
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your Rhabdomyosarcoma treatment journey.
Chief physician and professor. Grade 1 Expert at the Cancer Center, West China Hospital, Sichuan University (ranked No. 2 in China). Completed a postdoctoral fellowship in interventional radiology at the Chinese PLA General Hospital. Leads multidisciplinary team (MDT) care for complex tumors. Expert in minimally invasive interventional oncology for liver, lung, and pancreatic cancers.
Accreditations: Council Member, WATA. Member of CACA and CMDA committees on intervention, ablation, radioactive seeds, and pain. In 2023, inaugural director member, Palliative Care Committee, Sichuan MDA. Editorial board member of the Chinese Journal of Interventional Imaging and Therapy. Editorial board member of the Chinese Journal of Pain Medicine.
Leads 2 provincial S&T projects and 2 NSFC projects. Has 40+ papers, with 30+ as first or corresponding author. Highest impact factor: 10.73. Hepatocellular carcinoma (HCC) cohort: TACE + lenvatinib vs TACE + sorafenib. OS 18.97 vs 10.77 months. PFS 10.6 vs 5.4 months. ORR 66.8% vs 33.3%.
Dr. He Weibing is a pioneer of argon-helium cryoablation in China with more than 20 years of frontline practice. He was a founding member of Fuda Cancer Hospital (Guangzhou). He co-founded its Minimally Invasive Tumor Treatment Center and served as Executive Deputy Director. He also helped found the Ablation Group of the China Anti-Cancer Association. He has been the primary operator in more than 10,000 procedures.
He specializes in tumor cryoablation and is proficient in 125I seed brachytherapy, with a focus on liver and lung cancers. He proposed ten argon-helium techniques. Key co-authored data include: lung cryotherapy n=508; NSCLC n=120 (CR 25.5%, PR 41.8%, 6/12/24-month survival 64%/55%/36%); pancreatic cancer n=38 (median survival 12 months). He served on editorial boards in 2008 and 2010. He has been a national trainer for Varian and Boston Scientific since 2001.
Professor Luo Xiaoping is a nationally recognized interventional radiologist and a leading authority in Western China. He began pioneering vascular interventions in the early 1990s. He helped found the Interventional Group at the Second Affiliated Hospital of Chongqing Medical University.
He has completed over 100,000 interventional procedures, including about 4,000 complex cases. His key skills include TACE for hepatocellular carcinoma, Budd–Chiari interventions, TIPS, and single-stage bilateral stenting for hilar biliary obstruction, with success rates near 100%. He has been a master’s supervisor since 2007. He has trained many physicians, guided complex cases at more than 40 major hospitals across Western China, and helped build interventional programs. He has published 32 papers as first or corresponding author (22 CSCD core, 4 Chinese core, 6 CSCD extended).
Dr. Liu Shi Xin is the Vice Chairman of the Radiation Oncology Branch of the Chinese Medical Association. He serves as the Discipline Leader of the Oncology Center at Xiamen Humanity Hospital. Dr. Liu specializes in precision radiotherapy for thoracic and abdominal cancers. He is a recipient of the State Council Special Government Allowance for his medical contributions.
Leading Chinese oncology centers follow international protocols by utilizing the CCCG-RMS framework. This structure directly aligns with the US Children Oncology Group and European standards. Multi-disciplinary teams in cities like Guangzhou and Xiamen use standardized risk stratification. These methods match global diagnostic metrics.
Bookimed Expert Insight: A major quality signal in China is the presence of specialized pediatric supervisors. Professor Liu Shi Xin at Xiamen Humanity Hospital holds doctoral supervisor status and national honors. This level of seniority often correlates with high-volume centers that manage complex, rare pediatric sarcomas. Choosing a facility with JCI accreditation ensures rigorous international safety and administrative standards are met.
Patient Consensus: Families emphasize that verifying pathology and staging results is the most critical first step. They note that survival success depends heavily on a hospital's ability to coordinate surgery and radiation in one location.
Standard chemotherapy cycles in China typically follow a 21-day or 28-day schedule. Practitioners prioritize inpatient administration for the first 1 to 3 days of each cycle. This model allows for intensive hydration and clinical monitoring. It adheres to established Chinese Society of Clinical Oncology (CSCO) protocols.
Bookimed Expert Insight: China's oncology infrastructure is built for high-volume standardized care. Fuda Cancer Hospital alone treats over 30,000 international patients. This scale allows clinics to offer over 10 types of minimally invasive therapies. These often serve as alternatives or adjuncts to traditional chemotherapy. Patients should confirm if their protocol includes these specialized interventions early.
Patient Consensus: Parents of pediatric patients note that cycles often depend on blood count recovery. They emphasize that hospital workflows are very fast and standardized. Expect frequent blood labs and bundled supportive care like growth-factor shots during the rest period.
Proton beam therapy is available for rhabdomyosarcoma in China. Major oncology hubs in Shanghai and Guangzhou utilize this precision radiation. These centers effectively treat pediatric and adult soft-tissue sarcomas. Key technologies include active pencil beam scanning and intensity-modulated proton therapy.
Bookimed Expert Insight: While several Chinese centers possess proton technology, expertise in pediatric cases varies significantly. Dr. Liu Shi Xin at Xiamen Humanity Hospital holds leadership roles in national particle therapy committees. Working with a doctor of this caliber ensures the treatment plan aligns with rigorous national standards. Patients should prioritize centers where the radiation lead has extensive experience in both oncology and particle therapy.
Patient Consensus: Families often seek proton therapy specifically to reduce long-term side effects in children. Patients note that finding a high-volume sarcoma team is as vital as the technology itself.
Top hospitals for rhabdomyosarcoma in China include JCI-accredited Fuda Cancer Hospital and Xiamen Humanity Hospital. These centers specialize in multidisciplinary pediatric oncology. They utilize advanced therapies like cryosurgery and precise radiation. Many facilities integrate international protocols to improve outcomes for rare soft tissue sarcomas.
Bookimed Expert Insight: Patient data shows that choosing a hospital with high international volume like Fuda is vital. This clinic has served patients from over 100 countries. Such centers often have more experience with the logistics needed for rare sarcoma cases. They typically offer more flexible, minimally invasive options than standard public hubs.
Patient Consensus: Families emphasize starting treatment with a sarcoma-aware biopsy to avoid surgical complications. Many recommend prioritizing large referral hospitals that host dedicated multidisciplinary tumor boards for rare cancers.
China is a global hub for pediatric oncology trials and novel targeted therapies. The National Medical Products Administration fast-tracks over 60% of oncology agents. Patients access chimeric antigen receptor cell therapies and tyrosine kinase inhibitors. Specialized centers in Guangzhou and Xiamen offer advanced molecular profiling for rare sarcomas.
Bookimed Expert Insight: While trials are numerous, access at centers like Fuda Cancer Hospital depends on specific hospital-run protocols. Our data shows oncology hospitals in China frequently apply over 10 types of minimally invasive therapies. This volume suggests patients should prioritize academic centers with JCI accreditation to ensure rigorous clinical trial standards.
Patient Consensus: Patients emphasize that molecular profiling is a necessary first step before pursuing targeted therapy. Many note that language barriers and record translations are significant hurdles when accessing experimental protocols.
Chinese sarcoma centers provide advanced localized therapies including High-Intensity Focused Ultrasound, cryosurgery, and NanoKnife. These minimally invasive techniques target tumors while preserving healthy tissue and organ function. JCI-accredited facilities like Fuda Cancer Hospital combine these procedures with precision radiotherapy to manage complex or recurrent rhabdomyosarcoma cases effectively.
Bookimed Expert Insight: Patient data from Fuda Cancer Hospital highlights a significant trend toward multi-modality local control. Clinics often employ over 10 types of minimally invasive therapies. This approach is specifically used for late-stage cancers to avoid intensive chemotherapy. Choosing centers with high patient volumes, like those serving over 30,000 international patients, ensures access to these concentrated technologies under one roof.
Patient Consensus: Patients note that Chinese centers often prioritize limb-sparing reconstructions over amputation for large tumors. Many families appreciate the willingness to perform repeat local treatments for recurrences rather than switching solely to systemic palliative care.